Meir Panim delivers warmth, special care to families in need.
Japan’s largest pharmaceutical company, Takeda, recently signed an agreement with Teva Pharmaceutical Industries to commercialize the Israeli company’s innovative treatment for Parkinson’s disease, rasagiline, in Japan.
The rasagiline tablets, which are approved in over 40 countries for the treatment of Parkinson’s disease, gained UK and EU-marketing authorization in 2005 and US FDA approval in 2006.
“It is estimated there are about 150,000-180,000 people diagnosed with Parkinson’s disease in Japan, many of whom are waiting for a new treatment option,” said Nancy Joseph-Ridge, M.D., General Manager of Takeda’s Pharmaceutical Development Division located in Osaka, Japan in a press release on April 27.
“We will continue working on the development in cooperation with Teva so that we can bring this medicine to Japanese patients as quickly as possible,” Joseph-Ridge said.
“This agreement represents Teva’s continued commitment to introducing our innovative medicines to patients in Japan,” added Teva Global R&D president and Chief Scientific Officer, Dr. Michael Hayden.
Teva and Takeda entered an agreement in December 2013 to develop glatiramer acetate for the treatment of multiple sclerosis.
Developed by Teva, rasagiline was initially discovered by two Haifa Technion professors, John Finberg and Moussa Youdim, who were instrumental in the early clinical development of the anti-Parkinson drug.
Parkinson’s disease is a degenerative disorder of the central nervous system, whose symptoms include shaking, rigidity, slowness of movement and difficultly with walking as well as dementia in advanced stages. An estimated seven to 10 million people suffer from the disease across the world according to the Parkinson’s Disease Foundation.
According to Teva’s website, rasagiline is a monoaxmine oxidase B (MAO-B) inhibitor that increases available synaptic dopamine in the brain, which might improve the motor symptoms characteristic of Parkinson’s, slowing the progression of the disease.
“Rasagiline has an established safety and efficacy profile…[it] will be an important product for Japan, where the number of available treatment options for Parkinson’s disease remains limited,” said Dr. Hayden.
About the Author: Anav Silverman is a regular contributor to Tazpit News Agency.
If you don't see your comment after publishing it, refresh the page.
Comments are closed.
The Prime Minister told the Cabinet the deal in the works is even worse than feared.
Don’t expect Iran to sign anything before the last minute, if not afterwards, and if at all.
With “congratulations” like these, who needs a punch in the stomach?
The discovery would be a death blow the PA claims that Tel Aviv is “Palestinian” if it weren’t for the fact that that Arafat was born in Egypt.
Who is Horowitz? He’s Netanyahu’s eyes and ears. He’s very close to him, literally his personal representative everywhere…
“The US negotiating team are mainly there to speak on Iran’s behalf with
other members of the 5+1 countries and convince them of a deal.”
Saudi Arabia withdraws personnel from Aden. Iran calls Saudi strike a “strategic mistake.”
“The tone of #US officials’ background comments on #Iran talks is getting progressively more dreary, like the weather in #Lausanne,” Associate Press reporter Matt Lee tweeted Saturday night. Lee is a veteran journalist who has a keen eye and ear that cuts through the double talk and dishonest smiling faces of American diplomats. If he […]
It is a long tradition in the Muslim world never to agree to anything at an agreed time.
Hamas test fired a rocket on Saturday, the rocket landed within the Gaza Strip.
Gere is a guest of Shimon Peres.
Israel was aware of the report’s impending release and did not object.
The PA hasn’t changed anything on their end, so why did Netanyahu suddenly change his policy?
Obama’s “two-state” phobia shows how much he and his experts do not understand the Middle East.
With one week to go before Passover, 110 new Ukrainian immigrants landed in Israel on Tuesday morning, March 24. The majority of newcomers are refugees who fled the fighting zones in the eastern part of the Ukraine including the husband of a woman killed by a direct rock hit that slammed into their house in […]
The employees of Israel’s Knesset are also completing preparations as they bid farewell to those Knesset Members leaving and welcome new members to Israel’s parliament building.
Wein’s artwork depicting his journey to recovery recently won first place in a unique art competition.
How the volume made its way from a 17th-century Frankfurt printing press to finding its twin in Haifa is a fascinating story.
The app placed first among 800 other nominees as the contest, which has been described as the Oscars for the mobile world.
It was probably the first time that the marble relief portrait of Moses hanging in the House Chamber ever received such public acknowledgement.
Printed from: http://www.jewishpress.com/news/breaking-news/tevas-parkinson-drug-now-marketed-in-japan/2014/05/29/
Scan this QR code to visit this page online: